Kevin Feeley Sells 402 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 402 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the sale, the chief financial officer now owns 5,044 shares in the company, valued at $454,212.20. The trade was a 7.38 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total value of $362,565.79.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total value of $108,737.20.

GeneDx Stock Performance

WGS stock traded up $7.68 during midday trading on Friday, reaching $104.39. 704,762 shares of the company's stock traded hands, compared to its average volume of 617,273. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 52-week low of $8.10 and a 52-week high of $115.60. The stock has a market cap of $2.93 billion, a P/E ratio of -53.26 and a beta of 1.91. The stock's 50-day moving average is $84.59 and its 200 day moving average is $71.15.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. As a group, analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System lifted its holdings in GeneDx by 13.3% during the fourth quarter. California State Teachers Retirement System now owns 11,384 shares of the company's stock valued at $875,000 after purchasing an additional 1,335 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new position in shares of GeneDx during the 4th quarter valued at $1,007,000. Palisades Investment Partners LLC bought a new position in GeneDx in the 4th quarter worth $6,425,000. Castleark Management LLC purchased a new stake in GeneDx in the 4th quarter worth $4,743,000. Finally, PharVision Advisers LLC bought a new stake in GeneDx during the fourth quarter valued at about $301,000. 61.72% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.